Generation of binder-format-payload conjugate-matrices by antibody chain-exchange
- Nat Commun. 2024 Oct 31;15(1):9406. doi: 10.1038/s41467-024-53730-3.
- 1. Roche Pharma Research and Early Development (pRED), Large Molecule Research (LMR), Roche Innovation Center Munich, Penzberg, Germany.
- 2. Veraxa Biotech, Heidelberg, Germany.
- 3. Institute of Molecular Immunology, School of Medicine and Health, Technical University Munich (TUM), Munich, Germany.
- 4. Roche Pharma Research and Early Development (pRED), Large Molecule Research (LMR), Roche Innovation Center Munich, Penzberg, Germany. [email protected].
- # Contributed equally.
The generation of antibody-drug conjugates with optimal functionality depends on many parameters. These include binder epitope, antibody format, linker composition, conjugation site(s), drug-to-antibody ratio, and conjugation method. The production of matrices that cover all possible parameters is a major challenge in identifying optimal antibody-drug conjugates. To address this bottleneck, we adapted our Format Chain Exchange technology (FORCE), originally established for bispecific antibodies, toward the generation of binder-format-payload matrices (pair-FORCE). Antibody derivatives with exchange-enabled Fc-heterodimers are combined with payload-conjugated Fc donors, and subsequent chain-exchange transfers payloads to antibody derivatives in different formats. The resulting binder-format-conjugate matrices can be generated with cytotoxic payloads, dyes, haptens, and large molecules, resulting in versatile tools for ADC screening campaigns. We show the relevance of pair-FORCE for identifying optimal HER2-targeting antibody-drug conjugates. Analysis of this matrix reveals that the notion of format-defines-function applies not only to bispecific antibodies, but also to antibody-drug conjugates.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Drug-Linker Conjugates for ADCResearch Areas: Cancer